BioLineRx Ltd. (BLRX) shares surged 45.88 percent to $5.66, up $1.83 on Friday, after announcing that new data from its Phase 2 CheMo4METPANC clinical trial will be presented at the 2025 ASCO Annual Meeting. BioLineRx is currently trading at $7.11, compared to a previous close of $3.88 on the Nasdaq. The stock opened at $5.80 and has ranged between $5.25 and $7.77 on the day, with trading volume exceeding 26.5 million shares. Its 52-week range is $2.30 to $35.60.
The trial evaluates BioLineRx's CXCR4 inhibitor motixafortide in combination with the PD-1 inhibitor cemiplimab and standard chemotherapies for first-line treatment of pancreatic cancer. Updated results from the pilot phase showed that four of eleven patients remained progression-free for over a year.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.